tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Nail Diseases D009260 2 associated lipids
Paronychia D010304 3 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Dyspnea D004417 10 associated lipids
Vascular Diseases D014652 16 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Listeriosis D008088 12 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Ascites D001201 25 associated lipids
Albuminuria D000419 18 associated lipids
Anemia D000740 21 associated lipids
Osteomalacia D010018 5 associated lipids
Tremor D014202 15 associated lipids
Pemphigoid, Bullous D010391 8 associated lipids
Vasculitis D014657 14 associated lipids
Hypothermia D007035 19 associated lipids
Parkinson Disease D010300 53 associated lipids
Down Syndrome D004314 18 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Keloid D007627 12 associated lipids
Nephritis D009393 19 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Respiration Disorders D012120 5 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Facial Neoplasms D005153 3 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Influenza, Human D007251 11 associated lipids
Immune System Diseases D007154 3 associated lipids
Headache D006261 4 associated lipids
Cystitis D003556 23 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
HIV Infections D015658 20 associated lipids
Drug Eruptions D003875 30 associated lipids
Folliculitis D005499 7 associated lipids
Blindness D001766 6 associated lipids
Oliguria D009846 2 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Graves Disease D006111 6 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Gout D006073 4 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Choline Deficiency D002796 16 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Biliary Fistula D001658 13 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Renal Insufficiency D051437 8 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Loss M et al. Influence of long-term cyclosporine or FK 506 therapy on glucose and lipid metabolism in stable liver graft recipients. 1995 Transplant. Proc. pmid:7533365
Senninger N et al. Glucose metabolism following liver transplantation and immunosuppression with cyclosporine A or FK 506. 1995 Transplant. Proc. pmid:7533364
Mor E et al. Weight gain and lipid profile changes in liver transplant recipients: long-term results of the American FK506 Multicenter Study. 1995 Transplant. Proc. pmid:7533363
Söderdahl G et al. FK 506 improves recovery of bile secretion following orthotopic liver transplantation in man. 1995 Transplant. Proc. pmid:7533362
Bäckman L et al. Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group. 1995 Transplant. Proc. pmid:7533361
Abouljoud MS et al. Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group. 1995 Transplant. Proc. pmid:7533360
Mueller AR et al. The superior immunosuppressant according to diagnosis: FK 506 or cyclosporine A. 1995 Transplant. Proc. pmid:7533359
Porayko MK et al. Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US Multicenter trial. U.S. Multicenter Liver Study Group. 1995 Transplant. Proc. pmid:7533358
Platz KP et al. OKT3 vs FK 506 rescue management of acute steroid-resistant and chronic rejection. 1995 Transplant. Proc. pmid:7533357
Yasuhara M et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. 1995 Transplant. Proc. pmid:7533356
Schwartz M et al. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization. 1995 Transplant. Proc. pmid:7533355
Rucay P et al. FK 506 as treatment of late acute rejection in liver transplant patients. 1995 Transplant. Proc. pmid:7533354
Jain AB et al. One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events. 1995 Transplant. Proc. pmid:7533353
McDiarmid SV et al. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial. 1995 Transplantation pmid:7533345
Cox KL et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. 1995 Transplantation pmid:7533344
Shapiro R et al. A prospective randomized trial of FK506-based immunosuppression after renal transplantation. 1995 Transplantation pmid:7533343
Cameron AM et al. Immunophilin FK506 binding protein associated with inositol 1,4,5-trisphosphate receptor modulates calcium flux. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7533300
Fruman DA et al. FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells. 1995 Eur. J. Immunol. pmid:7533090
Ning YM and Sanchez ER Stabilization in vitro of the untransformed glucocorticoid receptor complex of S49 lymphocytes by the immunophilin ligand FK506. 1995 J. Steroid Biochem. Mol. Biol. pmid:7532989
Morikawa K et al. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. 1994 Antimicrob. Agents Chemother. pmid:7532933
Van Thiel DH et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. 1995 Am. J. Gastroenterol. pmid:7532912
Cao W et al. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. 1995 Transplantation pmid:7532879
Surdacka E et al. [New immunosuppressive drugs in transplantation]. 1994 Prz. Lek. pmid:7532870
Dawson VL et al. Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. 1994 Neuropharmacology pmid:7532825
Wang CR et al. T cell receptor-mediated signaling events in CD4+CD8+ thymocytes undergoing thymic selection: requirement of calcineurin activation for thymic positive selection but not negative selection. 1995 J. Exp. Med. pmid:7532685
Venkataraman L et al. FK506 inhibits antigen receptor-mediated induction of c-rel in B and T lymphoid cells. 1995 J. Exp. Med. pmid:7532676
Kawai M et al. Pyrrolidine dithiocarbamate inhibits intercellular adhesion molecule-1 biosynthesis induced by cytokines in human fibroblasts. 1995 J. Immunol. pmid:7532665
Donnelly JG and Soldin SJ Partial characterization of a 52 kDa CsA/FK506/rapamycin binding protein. 1994 Clin. Biochem. pmid:7532557
Murthy JN et al. Identification of a 14 kDa FK-506/rapamycin binding immunophilin from calf thymus. 1994 Clin. Biochem. pmid:7532556
Shapiro R et al. A prospective, randomized trial of FK-506 in renal transplantation--a comparison between double- and triple-drug therapy. 1994 Clin Transplant pmid:7532475
Konishi M et al. Effects of FK506 on surface antigen expression by regenerating thymocytes after sublethal irradiation in the rat. 1994 Thymus pmid:7532330
Wolter K et al. Interaction between FK 506 and clarithromycin in a renal transplant patient. 1994 Eur. J. Clin. Pharmacol. pmid:7532134
Marx SO et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. 1995 Circ. Res. pmid:7532117
Ryffel B et al. Nephrotoxicity of immunosuppressants in rats: comparison of macrolides with cyclosporin. 1994 Nov-Dec Exp. Nephrol. pmid:7532090
McCauley J The nephrotoxicity of FK506 as compared with cyclosporine. 1993 Curr. Opin. Nephrol. Hypertens. pmid:7532089
Cacciarelli TV et al. Influence of the timing of FK 506 (Tacrolimus) administration on recovery of renal function from warm ischemic injury in rats. 1994 Oct-Dec ASAIO J. pmid:7532042
Richter A et al. Growth inhibitory effects of FK506 and cyclosporin A independent of inhibition of calcineurin. 1995 Biochem. Pharmacol. pmid:7531976
Foster CA et al. Pharmacological modulation of endothelial cell-associated adhesion molecule expression: implications for future treatment of dermatological diseases. 1994 J. Dermatol. pmid:7531725
Timerman AP et al. Characterization of an exchange reaction between soluble FKBP-12 and the FKBP.ryanodine receptor complex. Modulation by FKBP mutants deficient in peptidyl-prolyl isomerase activity. 1995 J. Biol. Chem. pmid:7531689
Lemster BH et al. IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. 1995 Clin. Exp. Immunol. pmid:7531627
Sekigawa I et al. FK506 can inhibit apoptotic cell death induced by the HIV-1 envelope glycoprotein gp120. 1994 AIDS pmid:7531458
Fukuzaki T et al. A protocol with FK 506 for inducing unresponsiveness to murine islet allografts. 1995 Surgery pmid:7531371
Bennett WM et al. Nephrotoxicity of immunosuppressive drugs. 1994 Miner Electrolyte Metab pmid:7531274
Chen TS et al. Microbial transformation of immunosuppressive compounds. IV. Hydroxylation and hemiketal formation of ascomycin (immunomycin) by Streptomyces sp. MA 6970 (ATCC No. 55281). 1994 J. Antibiot. pmid:7531195
Whiting PH Acute and chronic nephrotoxicity associated with immunosuppressive drugs. 1994 Curr. Opin. Nephrol. Hypertens. pmid:7531104
Borel JF and Baumann G Molecular mechanisms of immunosuppressive agents. 1994 Bull. Mem. Acad. R. Med. Belg. pmid:7531051
Todo S et al. Abdominal multivisceral transplantation. 1995 Transplantation pmid:7530873
Gruessner RW et al. A prospective study of FK506 versus CsA and pig ATG in a porcine model of small bowel transplantation. 1995 Transplantation pmid:7530871
Heeckt PF et al. Functional impairment of enteric smooth muscle and nerves caused by chronic intestinal allograft rejection regresses after FK506 rescue. 1995 Transplantation pmid:7530870
Neuhaus P et al. Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. 1995 Transplantation pmid:7530868
Fruman DA et al. The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells. 1995 J. Immunol. pmid:7530743
Leach KL et al. A soluble binding assay for measuring 3H-FK506 binding to the hsp56 immunophilin. 1994 J Immunoassay pmid:7530727
Tsuchida M et al. Effects of irradiation, glucocorticoid and FK506 on cell-surface antigen expression by rat thymocytes: a three-colour flow cytofluorometric analysis. 1994 Immunology pmid:7530693
Karanam BV et al. FK 506 metabolism in human liver microsomes: investigation of the involvement of cytochrome P450 isozymes other than CYP3A4. 1994 Sep-Oct Drug Metab. Dispos. pmid:7530623
Dawson TM et al. The immunophilins, FK506 binding protein and cyclophilin, are discretely localized in the brain: relationship to calcineurin. 1994 Neuroscience pmid:7530348
Petros AM and Fesik SW Nuclear magnetic resonance methods for studying protein-ligand complexes. 1994 Meth. Enzymol. pmid:7530321
Eng WK et al. The yeast FKS1 gene encodes a novel membrane protein, mutations in which confer FK506 and cyclosporin A hypersensitivity and calcineurin-dependent growth. 1994 Gene pmid:7530227
Wera S et al. Rapamycin, FK506 and cyclosporin A inhibit human prolactin gene expression. 1995 FEBS Lett. pmid:7530217
Zarnt T et al. Time-dependent inhibition of peptidylprolyl cis-trans-isomerases by FK506 is probably due to cis-trans isomerization of the inhibitor's imide bond. 1995 Biochem. J. pmid:7529995
Shipston MJ et al. Glucocorticoid negative feedback in pituitary corticotropes. Pivotal role for calcineurin inhibition of adenylyl cyclase. 1994 Ann. N. Y. Acad. Sci. pmid:7529975
Peattie DA et al. Three distinct messenger RNAs can encode the human immunosuppressant-binding protein FKBP12. 1994 Gene pmid:7529739
Braun W et al. Three-dimensional structure and actions of immunosuppressants and their immunophilins. 1995 FASEB J. pmid:7529736
Atcherson MM and Trifillis AL Cytotoxic effects of FK506 on human renal proximal tubule cells in culture. 1994 In Vitro Cell. Dev. Biol. Anim. pmid:7529625
Clardy J The chemistry of signal transduction. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7529414
Alamartine E et al. In-vitro effects of cyclosporin A, FK506, 6-mercaptopurine, and prednisolone on lymphokine-activated killer cells. 1994 Nephrol. Dial. Transplant. pmid:7529381
Morozumi K and Takeda A [Kidney disorders induced by immunosuppressive agents]. 1994 Nippon Naika Gakkai Zasshi pmid:7529294
Burkhalter EL et al. Severe neurological complications following orthotopic liver transplantation in patients receiving FK 506 and prednisone. 1994 J. Hepatol. pmid:7529272
Cardenas ME et al. Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands. 1994 EMBO J. pmid:7529175
Kraus-Friedmann N and Feng L Reduction of ryanodine binding and cytosolic Ca2+ levels in liver by the immunosuppressant FK506. 1994 Biochem. Pharmacol. pmid:7529023
Coghlan VM et al. Association of protein kinase A and protein phosphatase 2B with a common anchoring protein. 1995 Science pmid:7528941
Douglas CM et al. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7528927
Sandborn WJ et al. Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue. 1995 Hepatology pmid:7528712
Chaudhuri B et al. The interaction between the catalytic A subunit of calcineurin and its autoinhibitory domain, in the yeast two-hybrid system, is disrupted by cyclosporin A and FK506. 1995 FEBS Lett. pmid:7528690
Klaus GG et al. Properties of mouse CD40. Ligation of CD40 activates B cells via a Ca(++)-dependent, FK506-sensitive pathway. 1994 Eur. J. Immunol. pmid:7528676
Moudgil A et al. Inhibition of in vitro immunoglobulin production by a novel immunosuppressive drug brequinar sodium. 1994 Transplant Sci pmid:7528627
Echigo Y et al. Effects of cyclosporine and tacrolimus (FK 506) on acute pancreatitis in mice. 1995 Arch Surg pmid:7528496
Bennett WM et al. Nephrotoxicity of immunosuppressive drugs. 1994 Nephrol. Dial. Transplant. pmid:7528363
Monfar M et al. Activation of pp70/85 S6 kinases in interleukin-2-responsive lymphoid cells is mediated by phosphatidylinositol 3-kinase and inhibited by cyclic AMP. 1995 Mol. Cell. Biol. pmid:7528328
Sugiyama E et al. FK506, an immunosuppressant, partially inhibits interleukin 6 production by adherent rheumatoid synovial cells. 1994 J. Rheumatol. pmid:7528280
Hachida M et al. [The rescue effect of FK506 in refractory rejection after cardiac transplantation]. 1994 Nihon Kyobu Geka Gakkai Zasshi pmid:7528255
Stan R et al. Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue. 1994 J. Biol. Chem. pmid:7528205
Yli-Kauhaluoma J and Janda KD Twisted alpha-keto amides as transition-state analogues for acyl-transfer reactions: synthesis of the immunoconjugates. 1994 Bioorg. Med. Chem. pmid:7528089
Suzuki S FK506 and deoxyspergualin: experimental studies and clinical applications. 1994 Transpl. Immunol. pmid:7528087
Hossain M et al. Eosinophil viability-enhancing activity in mite-sensitive bronchial asthma. 1994 Intern. Med. pmid:7528071
Yamamoto S and Kato R Hair growth-stimulating effects of cyclosporin A and FK506, potent immunosuppressants. 1994 J. Dermatol. Sci. pmid:7528050
Tanabe M et al. The influence of donor and recipient strains in isolated small bowel transplantation in rats. 1994 Transplant. Proc. pmid:7527986
Mueller AR et al. Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease. 1994 Transplant. Proc. pmid:7527984
Lemmens HP et al. Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis. 1994 Transplant. Proc. pmid:7527983
Reggiani P et al. Conversion to rescue therapy with FK 506: data from eight liver transplant patients. 1994 Transplant. Proc. pmid:7527982
Kinoshita I et al. Immunosuppression with FK 506 insures good success of myoblast transplantation in MDX mice. 1994 Transplant. Proc. pmid:7527978
Asselin I et al. Polymerase chain reaction-based assay to assess the success of myoblast transplantation in mdx mice. 1994 Transplant. Proc. pmid:7527970
Tsugita M et al. Hepatocytes or liver nonparenchymal cells plus FK 506 prolong liver xenograft survival. 1994 Transplant. Proc. pmid:7527969
Ricordi C et al. Donor bone marrow cell infusion without recipient cytoablation induces acceptance of rat islet allografts. 1994 Transplant. Proc. pmid:7527967
Ericzon BG Early graft function in liver transplantation patients. 1994 Transplant. Proc. pmid:7527965
Morris R Modes of action of FK506, cyclosporin A, and rapamycin. 1994 Transplant. Proc. pmid:7527964
Frei U and Wagner K Renal function in liver transplant patients receiving FK506 or cyclosporin A immunosuppressive therapy. 1994 Transplant. Proc. pmid:7527963
Sewing KF Pharmacokinetics, dosing principles, and blood level monitoring of FK506. 1994 Transplant. Proc. pmid:7527962
Neuhaus PJ Optimised first-line FK506-based protocols in liver transplantation: experience from the University Hospital Rudolf Virchow, Berlin. 1994 Transplant. Proc. pmid:7527961
Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK506-based immunosuppression. European FK506 Multicentre Liver Study Group. 1994 Transplant. Proc. pmid:7527960
Candinas D et al. Efficacy of leflunomide in combination with current immunosuppressive agents in rat cardiac allotransplantation. 1994 Transplant. Proc. pmid:7527959